Sitc 2025 Ak132. Kuantan Port SITC’s CBX2 New Service Kuantan Port (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking. The Women in Cancer Immunotherapy Network (WIN) is a SITC initiative seeking to promote and elevate women in the cancer immunotherapy field
Tallac Presents First Clinical Data for TAC001 at SITC 2023 Business from www.businesswire.com
The SITC Spring Scientific, Cellular Therapy for Solid Tumors, will address the recent advances in adoptive cellular therapy for solid tumors and rate-limiti. SITC Women in Cancer Immunotherapy Network (WIN) Leadership Institute
Tallac Presents First Clinical Data for TAC001 at SITC 2023 Business
SITC Women in Cancer Immunotherapy Network (WIN) Leadership Institute SITC 2025 is held in Washington DC, United States, from 11/5/2025 to 11/5/2025 in Gaylord National Resort and Convention Center. AK132 efficiently inhibits tumor growth in mice with subcutaneous MC38-hCD47hCLDN18.2 tumor.
Sitc 2024 Registration Zenia Annabella. 8, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926.HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47. SITC Women in Cancer Immunotherapy Network (WIN) Leadership Institute
SITC 2022 Held Successfully SI Digital Magazine. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking. AK132 efficiently inhibits tumor growth in mice with subcutaneous MC38-hCD47hCLDN18.2 tumor.